Therapeutic Targets in Innate Immunity to Tackle Alzheimer's Disease

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Alzheimer's disease (AD) is the leading cause of dementia, posing significant socioeconomic challenges.
• Traditional therapeutic strategies targeting beta-amyloid plaques and neurofibrillary tangles in AD have yielded limited success.
• Neuroinflammation is increasingly recognized as a critical factor in the pathogenesis and progression of neurodegenerative diseases, including AD.

Purpose of the Study:

• To review the role of neuroinflammation in Alzheimer's disease.
• To identify novel therapeutic targets within the innate immune system for AD.
• To discuss current drug research and challenges in modulating innate immunity for AD.

Main Methods:

• Literature review and synthesis of existing research on neuroinflammation in AD.
• Identification and discussion of key innate immune components implicated in AD pathology (microglia, TREM2, complement system, inflammasomes, cytosolic DNA sensors).
• Overview of ongoing therapeutic studies targeting these innate immune pathways.

Main Results:

• Neuroinflammation is a significant contributor to Alzheimer's disease pathology.
• Specific innate immune components like microglia, TREM2, complement system, inflammasomes, and cytosolic DNA sensors represent potential therapeutic targets.
• Several studies are actively investigating drugs targeting these innate immune pathways.

Conclusions:

• Targeting neuroinflammation offers a promising alternative therapeutic strategy for Alzheimer's disease.
• Modulating the innate immune system in AD requires careful consideration due to its complex and delicate nature.
• Further research into innate immune modulation holds potential for developing effective disease-modifying therapies for Alzheimer's disease.